The Latest Breaking News from Abbott Laboratories

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.51% on an annualized basis producing an average annual return of 15.1%. Currently, Abbott Laboratories has a market capitalization of $211.63 billion.

A whale with a lot of money to spend has taken a noticeably bearish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories (NYSE:ABT) we detected 11 strange trades.

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 3.32% on an annualized basis.

Parents who bought recalled infant formulas made by Abbott Laboratories are filing proposed class-action lawsuits against Abbott, as the U.S. Food and Drug Administration investigates reports of three babies who became sick and two who died after consuming the formulas.

Abbott Laboratories (NYSE: ABT) recalls powdered baby formulas, including Similac, made at a Michigan facility after

Despite the ongoing global public health crisis, fundamentally-sound companies focused on diabetic treatments are seemingly unfazed. So, given Senseonics' (SENS) relative overvaluation and bleak growth prospects, we think it could be wise to bet on diabetes stocks Novo Nordisk (NVO), Eli Lilly (LLY), and Abbott Laboratories (ABT). Let’s discuss.

Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

As people across the country continue to grab at-home, COVID-19 tests off store shelves, Abbott Laboratories — the maker of one of the most popular of those tests — reported a stellar fourth quarter and financial year.

Someone with a lot of money to spend has taken a bullish stance on Abbott Laboratories (NYSE:ABT). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.